Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667288 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Safety Study of A-101 Solution
A Phase 3 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT02667288 is a Phase 3 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 147 participants.
The verdict
NCT02667288, a Phase 3 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
Interventions
- DRUG A-101 Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667288
The ClinicalTrials.gov registry entry for NCT02667288 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A-101 Solution is the first listed.
NCT02667288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02667288 about?
NCT02667288 is a clinical study titled "An Open-Label Safety Study of A-101 Solution". This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
What is the current status of trial NCT02667288?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2016-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02667288?
The interventions under investigation include: A-101 Solution (DRUG).
Who is sponsoring clinical trial NCT02667288?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.